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The heptavalent pneumococcal conjugate vaccine (PCV7) was introduced in the United States (US) in 2000 and has
significantly reduced invasive pneumococcal disease; however, the incidence of nonvaccine serotype invasive disease,
particularly due to serotype 19A, has increased. The serotype 19A increase can be explained in part by expansion of a
genotype that has been circulating in the US prior to vaccine implementation (and other countries since at least 1990),
but also by the emergence of a novel ‘‘vaccine escape recombinant’’ pneumococcal strain. This strain has a genotype
that previously was only associated with vaccine serotype 4, but now expresses a nonvaccine serotype 19A capsule.
Based on prior evidence for capsular switching by recombination at the capsular locus, the genetic event that resulted
in this novel serotype/genotype combination might be identifiable from the DNA sequence of individual pneumococcal
strains. Therefore, the aim of this study was to characterise the putative recombinational event(s) at the capsular locus
that resulted in the change from a vaccine to a nonvaccine capsular type. Sequencing the capsular locus flanking
regions of 51 vaccine escape (progeny), recipient, and putative donor pneumococci revealed a 39 kb recombinational
fragment, which included the capsular locus, flanking regions, and two adjacent penicillin-binding proteins, and thus
resulted in a capsular switch and penicillin nonsusceptibility in a single genetic event. Since 2003, 37 such vaccine
escape strains have been detected, some of which had evolved further. Furthermore, two new types of serotype 19A
vaccine escape strains emerged in 2005. To our knowledge, this is the first time a single recombinational event has
been documented in vivo that resulted in both a change of serotype and penicillin nonsusceptibility. Vaccine escape by
genetic recombination at the capsular locus has the potential to reduce PCV7 effectiveness in the longer term.
Citation: Brueggemann AB, Pai R, Crook DW, Beall B (2007) Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 3(11):
e168. doi:10.1371/journal.ppat.0030168
Introduction
Streptococcus pneumoniae (the ‘‘pneumococcus’’) is one of the
most important bacterial pathogens worldwide, especially
among children. Pneumococcal pneumonia, meningitis, and
septicemia result in 1 million deaths annually among children
,5 y of age [1]. PCV7 protects against seven pneumococcal
capsular types (serotypes)—4, 6B, 9V, 14, 18C, 19F, and 23F
[2]—and has been used to vaccinate children in the United
States since 2000. PCV7 has been remarkably effective in
reducing disease among vaccinated children, and even among
unvaccinated children and adults as a result of a striking herd
immunity effect, due to the disruption of pneumococcal
transmission from young children to older children and
adults [2–6]. PCV7 is increasingly being used to vaccinate
children in other countries.
There are 91 known pneumococcal serotypes, the last of
which was discovered recently [7,8]. The ecological niche for
the vast majority of the pneumococcal population is the
nasopharynx of healthy children [9]; thus, any serotype-
speciﬁc vaccine that is of limited valency and affects
nasopharyngeal carriage will perturb the composition of the
circulating pneumococcal population, with unknown con-
sequences. The capsule is the principal known virulence
factor with respect to invasive pneumococcal disease [10], and
population biology studies indicated that certain serotypes
have a greater potential to cause invasive disease than others
[11,12]. Another important aspect of pneumococcal biology is
that there is a strong association between genotype as deﬁned
by multilocus sequence typing (MLST), and serotype—that is,
strains with the same MLST sequence type (ST) are usually of
the same serotype [11,13,14].
Since the capsule is the principal invasive disease determi-
nant, and is the target for serotype-speciﬁc prevention of
disease by vaccination, there are two events that are especially
important with respect to understanding vaccine effects:
serotype replacement and capsular switching. At a popula-
tion level, serotype replacement simply refers to a decrease in
the prevalence of vaccine serotype pneumococci in the
nasopharynx accompanied by a corresponding increase in
nonvaccine serotype pneumococci, as they ﬁll the newly
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pharynx of a healthy child may or may not be problematic;
the public health concern is whether or not replacement
serotypes also cause disease. Serotype replacement invasive
disease among children and adults has signiﬁcantly increased
in the US post-vaccination [15–18], and invasive pneumo-
coccal disease among children ,5 y of age is now predom-
inantly due to serotype 19A [17]. A recent JAMA report
described a signiﬁcant overall increase in nonvaccine
serotype disease among Native Alaskan children, most
frequently due to serotype 19A [18]. Genotypic character-
isation of these serotype 19A strains by MLST showed that
most of the serotype 19A replacement disease can be
explained by clonal expansion of one genotype, ST199, which
existed prior to vaccination [15,18].
The second major vaccine-related concern is the possibility
of capsular switching, when the genes encoding one type of
capsule are exchanged, via transformation and recombina-
tion, for the genes encoding a different type of capsule.
Capsular switches from one vaccine serotype to another were
ﬁrst described 16 y ago [19–21], but it is the vaccine-to-
nonvaccine serotype switch that is of primary concern, because
it contributes to serotype replacement and allows for the
possibility of vaccine escape. Acquisition of a nonvaccine
capsule by a pneumococcal strain capable of causing invasive
disease has been a serious concern related to the use of any
serotype-speciﬁc vaccine [11,22].
The capsular locus of the pneumococcus is located between
two genes, dexB and aliA ([7]; Figure 1). (Serotype 37 is one
exception, as it has a defective capsular locus and the
serotype is determined by the type 37 synthase gene [tts]
located elsewhere in the pneumococcal genome [7,23].) Two
of the six penicillin-binding proteins (PBPs) possessed by the
pneumococcus are near the capsular locus: pbp2x is upstream
of dexB and pbp1a is downstream of aliA. Alterations in PBPs
confer penicillin resistance, and alterations in pbp2x, pbp1a,
and pbp2b are the most important [24–26]. Penicillin-resistant
pneumococci are a major problem throughout the world [27];
prior to use of PCV7 in the US, nearly one-quarter of invasive
pneumococci were penicillin-nonsusceptible [28]. Initially,
use of PCV7 in the US reduced the incidence of invasive
disease due to antimicrobial-resistant vaccine serotypes, but
more recently, antimicrobial resistance has increased with the
increase of serotype 19A disease [28,29].
The Centers for Disease Control and Prevention (CDC) has
been monitoring invasive pneumococcal disease since 1995
through the Active Bacterial Core (ABC) surveillance pro-
gram [6,14,30] and as a result, the post-vaccination increase in
nonvaccine serotype 19A disease in the US was quickly
detected. Serotype 19A strains collected by the CDC through
2005 were genotyped by MLST, which revealed that vaccine
escape strains had begun to emerge in 2003 [14,15]. These
strains possessed an MLST genotype, ST695, that had always
been associated with vaccine serotype 4 (ST695
4), but now
expressed a serotype 19A capsule (ST695
19A). These strains
were detected only 3 y after vaccine implementation, but
rapidly increased in prevalence. The ﬁrst three strains were
detected in 2003; two strains were detected in 2004; and 32
strains were detected in 2005, some of which had evolved
further. Moreover, in 2005, two new types of serotype 19A
vaccine escape strains emerged, ST2365
19A (n ¼ 4) and
ST899
19A (n¼1); these appeared to represent new recombina-
tional events that also occurred between serotype 4 recipients
and serotype 19A donors. The aim of this study was to
sequence the regions upstream and downstream of the
capsular locus, including both PBPs, to identify the putative
recombinational event(s) that resulted in these vaccine escape
strains.
Results
Recipient, Donor, and Progeny Pneumococcal Strains
Selected for Characterisation
Strains were selected based upon serotyping and MLST
genotyping data and are described in Table 1. Between 1998
and 2005, 31,669 cases of invasive pneumococcal disease
among all ages were identiﬁed from ABC sites, from which
28,363 pneumococcal strains were available for serotyping.
15,736 (55%) strains were of nonvaccine serotypes, and 1,935
of those were serotype 19A, 88% of which were recovered
from 2000 to 2005 ([17] and ABC surveillance program,
unpublished data). The following serotype 19A strains were
genotyped by MLST: 82 of 113 (73%) strains from 1999
[14,31] and 779 of 1,597 (49%) strains from 2001 to 2005
([14,15] and ABC surveillance program, unpublished data).
No serotype 19A strains from 1998 or 2000 were genotyped
by MLST. Possible serotype 19A capsular switches were
identiﬁed among 57 of 779 (7%) of 2001–2005 genotyped
strains: ST271, 690, 899, 1092, and 1790 (n ¼ 1 strain each);
ST236, 338, and 557 (n¼2 strains each); ST230 and 292 (n¼3
strains each); ST156 (n¼4 strains); and ST695 (n¼37 strains)
[14,15,31]. Among these strains, the ST695
19A plus related
ST899
19A strains were characterised in this study. All other
possible capsular switch strains were present in very low
numbers and/or were also found outside the US; vaccine and
nonvaccine serotype variants of ST156 are recognised in the
global database (http://www.mlst.net/).
Recipient strains were those with the background genotype
into which the 19A capsular locus recombined: ST695
4 (n¼3),
recovered in 1999, and ST899
4 (n ¼ 1), recovered in 2002.
Based upon pulsed-ﬁeld gel electrophoresis, selected MLST
data, and eBURST analysis, it is likely that strains of ST899
4
were also common among children ,5 y of age before vaccine
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Author Summary
The 7-valent pneumococcal conjugate vaccine is a remarkable
public health success story. It has significantly reduced invasive
pneumococcal disease in the United States not only by protecting
vaccinated children, but also by protecting unvaccinated older
children and adults by herd immunity. However, there was always a
concern that use of a limited-valency vaccine would result in an
increase in disease due to nonvaccine serotypes, and this has now
occurred in the US. The predominant nonvaccine serotype causing
invasive disease is 19A, and this increase is partially explained by
‘‘vaccine escape’’ pneumococci, strains that have exchanged the
genes that encode a vaccine serotype 4 capsule for genes that
encode a nonvaccine serotype 19A capsule. These strains are then
able to escape vaccine-induced immunity. Characterisation of the
genetic event that resulted in these vaccine escape strains was the
focus of our study and the results were surprising. The results of this
study have important relevance to the long-term effectiveness of
the current vaccine and to the development of future pneumo-
coccal vaccines.introduction [14]. Putative donor strains of the 19A capsular
locus were selected from pneumococci recovered in 1999 and
2003. The most likely donor of the 19A capsular locus was
ST199
19A, because ST199
19A existed as a prevalent strain pre-
vaccine implementation and was the major clone responsible
for serotype replacement disease post-vaccine implementa-
tion [15,17]. Thus, four pre- and post-vaccine implementation
strains of ST199
19A were selected, plus one strain of ST645
19A,
which is a single-locus MLST variant of ST199
19A. All serotype
19A strains collected through 2005 that were ST695 or closely
related MLST genotypes were characterised as progeny
strains. This resulted in the characterisation of 42 unique
strains: ST695
19A (n¼36), ST2365
19A (n¼4), ST2363
19A (n¼1),
and ST899
19A (n ¼ 1).
Pneumococci were recovered from patients aged ,1t o9 6y
with invasive pneumococcal disease (Table 1). All pneumo-
cocci were recovered from blood, apart from one strain
(cdc46) that was recovered from cerebrospinal ﬂuid. Among
vaccine escape strains, 40 of 42 (95%) were collected in the
northeastern US (note that 37% of all 20,196 available isolates
since 2000 were from the Northeast; ABC surveillance
program, unpublished data); and two strains were from
Minnesota (cdc27) and Colorado (cdc21). Three putative
donor strains were from Georgia (cdc8, cdc9, and cdc11); all
other putative donor and recipient strains were collected in
the Northeast. All vaccine escape strains were recovered from
2003 to 2005. Strains from 2003 to 2004 were recovered from
children  4 y of age, although only pediatric isolates were
genotyped [15]; 2005 strains were recovered from children
and adults.
Sequence Homology within Regions Flanking the
Capsular Locus
Regions upstream and downstream of the capsular locus
were sequenced in all 51 pneumococci (Figure 1). Sequence
alignment comparisons showed that recipient, donor, and
progeny strains could be grouped based upon the relatedness
of the regions ﬂanking the capsular locus, considered as one
joined sequence of 20.6 kb (Figure 1). The capsular locus has
not yet been sequenced, but serotypes have been conﬁrmed
phenotypically, and the serotypes of a subset of the vaccine
escape strains were conﬁrmed by a PCR assay [32]. The
capsular locus is considered here only as it encodes either a
serotype 4 or 19A capsule.
Progeny strains consisted of three groups, P1,P 2, and P3
(Table 1). Twenty-seven ST695
19A progeny strains (P1) were
identical to each other in the capsular locus ﬂanking regions
and were the major group of vaccine escape strains. There
were ﬁve additional P1 variants, all of which differed from the
P1 strains by only one to two single nucleotide polymor-
phisms (SNPs) over the entire region of sequence. Further-
more, one strain, P1var6, was a single-locus MLST variant of
the P1 strains at spi, but the capsular locus ﬂanking regions of
P1 and P1var6 were identical. P2 progeny strains and strain P3
were 0.3% and 1%, respectively, divergent from P1 progeny
over the entire region of sequence.
Among recipient strains, the ﬂanking sequences of cdc1,
cdc3, and cdc4 (R1) were identical; recipient strain cdc7 (R2)
was 0.5% divergent from R1 strains (Table 1). Among 19A
donor strains there were four unique sequences: cdc2 and
cdc8 (D1), cdc9 (D2), cdc11 (D3), and cdc6 (D4).
Recombinational Crossover Points and Likely Serotype
19A Donors among Progeny Strains
Sequence alignments of the capsular locus ﬂanking regions
revealed the upstream and downstream recombinational
crossover points in the ST695
19A strains. Three SNPs
(heterologous to donor and homologous to recipient) marked
and conﬁrmed the upstream crossover point, just upstream of
pbp2x; similarly, two SNPs marked and conﬁrmed the down-
Figure 1. Schematic of the Pneumococcal Genome
Housekeeping genes characterised in the MLST scheme (aroE, gdh, gki, recP, spi, xpt, and ddl), the genes for PBPs (pbp2x,- 1a,- 3,- 2b,- 2a, and -1b), the
capsular locus flanked by the dexB and aliA genes, and the region around the capsular locus that was sequenced in this study (shown also in expanded
version) are depicted. The capsular loci of serotypes 4 and 19A are 20.9 kb and 18.6 kb, respectively, in length.
doi:10.1371/journal.ppat.0030168.g001
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Pneumococcal Vaccine EscapeTable 1. Description of the Pneumococcal Strains Characterised in This Study
Strain Strain
Type
Group Year Sero-
type
ST MLST Allelic Profile Source Age
(y)
State
a Alleles MIC (lg/ml)
a
aroE gdh gki recP spi xpt ddl pbp2x pbp1a pen ery clin cot tet chlo lev
cdc1 Recipient R1 1999 4 695 16 13 4 4 6 113 18 Blood 4 CT 4 1 0.03 0.06 0.12 0.25 1 4 2
cdc3 Recipient R1 1999 4 695 16 13 4 4 6 113 18 Blood 2 NY 4 1 0.03 0.06 0.12 0.25 1 4 1
cdc4 Recipient R1 1999 4 695 16 13 4 4 6 113 18 Blood 1 CT 4 1 0.03 0.12 0.25 0.25 1 4 1
cdc7 Recipient R2 2002 4 899 16 13 4 4 6 10 18 Blood 73 MD 2 1 0.03 0.12 0.06 0.25 2 8 16
cdc2 Donor D1 1999 19A 199 8 13 14 4 17 4 14 Blood 1 NY 5 5
h 0.12 16 0.12 8 1 4 1
cdc8 Donor D1 2003 19A 199 8 13 14 4 17 4 14 Blood 3 GA 5 5 0.12 32
i 0.12 8 2 2 1
cdc9 Donor D2
b 2003 19A 199 8 13 14 4 17 4 14 Blood 1 GA 6 4 0.12 32
i 0.25 4 2 2 1
cdc11 Donor D3
b 2003 19A 199 8 13 14 4 17 4 14 Blood 1 GA 5 2 0.12 0.06 0.12 0.25 2 2 1
cdc6 Donor D4 1999 19A 645 7 13 14 4 17 4 14 Blood 95 CT 5 2 0.12 16 1 0.25 1 4 1
cdc10 Progeny P1
c 2003 19A 695 16 13 4 4 6 113 18 Blood ,1 CT 5 5rec
h 0.06 0.06 0.12 0.25 2 4 1
cdc13 Progeny P1 2003 19A 695 16 13 4 4 6 113 18 Blood 4 NY 5 5rec 0.06 0.06 0.06 0.25 4 4 1
cdc14 Progeny P1 2004 19A 695 16 13 4 4 6 113 18 Blood 3 CT 5 5rec 0.06 16
i 0.12 0.25 2 4 1
cdc16 Progeny P1 2004 19A 695 16 13 4 4 6 113 18 Blood ,1 NY 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc18 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 60 CT 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc19 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 73 NY 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc20 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 84 NY 5 5rec 0.06 0.06 0.06 0.25 2 4 1
cdc23 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 86 MD 5 5rec 0.06 0.06 0.06 0.25 2 4 1
cdc27 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 4 MN 5 5rec 0.06 0.03 0.12 0.25 2 4 1
cdc28 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 54 CT 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc29 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 4 NY 5 5rec 0.06 0.06 0.06 0.25 2 4 1
cdc30 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 68 CT 5 5rec 0.06 0.06 0.06 0.25 2 4 1
cdc31 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 79 NY 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc32 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 3 NY 5 5rec 0.12 0.06 0.06 0.25 2 4 1
cdc33 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 64 CT 5 5rec 0.06 16
i 0.12 0.25 2 4 1
cdc36 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 67 CT 5 5rec 0.12 0.06 0.06 0.25 2 4 1
cdc38 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 87 MD 5 5rec 0.12 0.06 0.06 0.25 2 4 1
cdc39 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 4 MD 5 5rec 0.12 16
i 0.06 0.25 2 4 1
cdc40 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 63 NY 5 5rec 0.12 0.06 0.06 0.25 2 4 1
cdc45 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 90 NY 5 5rec 0.06 0.06 0.12 0.5 2 4 1
cdc46 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 CSF
a 42 NY 5 5rec 0.06 0.06 0.12 0.5 2 4 1
cdc47 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 66 CT 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc48 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 69 CT 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc50 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 96 CT 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc51 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 7 CT 5 5rec 0.06 0.06 0.12 0.5 2 4 1
cdc52 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 77 CT 5 5rec 0.12 0.06 0.12 0.25 2 4 1
cdc53 Progeny P1 2005 19A 695 16 13 4 4 6 113 18 Blood 30 CT 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc12 Progeny P1var1
c 2003 19A 695 16 13 4 4 6 113 18 Blood 3 NY 5 5rec 0.12 0.06 0.12 0.25 2 4 1
cdc17 Progeny P1var1 2005 19A 695 16 13 4 4 6 113 18 Blood 1 CT 5 5rec 0.06 0.06 0.06 0.25 2 4 1
cdc22 Progeny P1var1 2005 19A 695 16 13 4 4 6 113 18 Blood 9 NY 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc43 Progeny P1var1 2005 19A 695 16 13 4 4 6 113 18 Blood 41 NY 5 5rec 0.12 0.06 0.12 0.25 2 4 1
cdc42 Progeny P1var2
c 2005 19A 695 16 13 4 4 6 113 18 Blood 78 NY 5 5rec 0.06 0.06 0.12 0.25 2 4 1
cdc44 Progeny P1var2 2005 19A 695 16 13 4 4 6 113 18 Blood 3 NY 5 5rec 0.12 0.06 0.12 0.25 2 8 1
cdc24 Progeny P1var3
c 2005 19A 695 16 13 4 4 6 113 18 Blood 8 CT 7
g 5rec 0.06 0.06 0.06 0.25 2 4 1
cdc34 Progeny P1var4
c 2005 19A 695 16 13 4 4 6 113 18 Blood 40 CT 5 5rec 0.06 16
i 0.06 0.25 2 4 1
cdc49 Progeny P1var5
c 2005 19A 695 16 13 4 4 6 113 18 Blood 91 CT 5 5rec 0.12 0.06 0.12 0.25 2 4 1
cdc37 Progeny P1var6
d 2005 19A 2363 16 13 4 4 136 113 18 Blood 49 CT 5 5rec 0.06 0.06 0.12 1 2 4 1
cdc25 Progeny P2
e 2005 19A 2365 16 13 4 5 6 197 14 Blood 79 NY 5 2 0.06 0.06 0.25 0.25 2 4 1
cdc26 Progeny P2 2005 19A 2365 16 13 4 5 6 197 14 Blood 42 NY 5 2 0.06 0.06 0.12 0.25 2 4 1
cdc35 Progeny P2 2005 19A 2365 16 13 4 5 6 197 14 Blood 40 CT 5 2 0.06 8
i 0.25 0.25 2 4 1
cdc41 Progeny P2var1
e 2005 19A 2365 16 13 4 5 6 197 14 Blood 29 NY 5 2 0.06 0.06 0.06 0.25 2 4 1
cdc21 Progeny P3
f 2005 19A 899 16 13 4 4 6 10 18 Blood 22 CO 3 3 0.03 0.06 0.12 0.25 2 4 1
aAbbreviations: CSF¼cerebrospinal fluid; CO¼Colorado; CT¼Connecticut; GA¼Georgia; MD¼Maryland; MN¼Minnesota; NY¼New York; MIC¼minimum inhibitory concentration; pen
¼ penicillin; ery ¼ erythromycin; clin ¼ clindamycin; cot ¼ cotrimoxazole; tet ¼ tetracycline; chlo ¼ chloramphenicol; lev ¼ levofloxacin.
bDonors D2 and D3 were not found among this collection of progeny.
cP1,P 1var1,P 1var2,P 1var3,P 1var4, and P1var5 were the progeny of recipient R1 and donor D1.
dP1var6 was the progeny of the recipient R1 and donor D1, with further evolution at the spi locus.
eP2 and P2var1 were the progeny of D4 and an unknown recipient.
fP3 was the progeny of recipient R2 and an unknown donor.
gpbp2x alleles 5 and 7 differ only by a single nucleotide polymorphism.
hAlleles 5 and 5rec are identical except for a single nucleotide polymorphism, which marks the downstream crossover point.
iStrains are efflux mef(A)-positive by PCR; cdc2 and cdc6 have not been tested.
doi:10.1371/journal.ppat.0030168.t001
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Pneumococcal Vaccine Escapestream crossover point, at the 39 end and just beyond the 39
end of pbp1a (Figures 2A and S1), resulting in a recombina-
tional fragment of 38.6 kb. To our knowledge, this is the ﬁrst
reported in vivo example of a recombinational event in
pneumococcus in which the capsular locus and both adjacent
PBPs recombined in what appeared to be a single event. This
was shown to be experimentally possible by Trzcinski and
colleagues [33].
The likely donor of the serotype 19A capsular locus and
ﬂanking regions in ST695
19A was ST199
19A. Although the
actual strain that donated the DNA cannot be identiﬁed with
certainty, it is represented by the pre- and post-vaccination
D1 strains from 1999 and 2003, respectively (Figures 2A and
S1).
Sequence alignments also revealed a second recombina-
tional event around the capsular locus in four strains of P2
progeny, all of which were ﬁrst identiﬁed in 2005. Three P2
strains were identical (or one SNP different, P2var1)t oD 4 in
the entire ﬂanking region sequenced (Figures 2B and S1),
suggesting that D4 was the likely donor of the 19A capsule
among P2 progeny strains.
The third type of 19A progeny strain identiﬁed in this
study was P3 (ST899
19A). ST899 appears to have circulated at
least since 1999 as a serotype 4 strain [14], but in 2005
appeared as a 19A serotype strain (Table 1). None of the
sequenced 19A donors in this study share distinctive regions
of homology to the P3 progeny; thus, the donor of this 19A
capsular locus is still unknown.
Relatedness Based on MLST Genotype
Figure 3 further clariﬁes the evolution of these vaccine
escape strains by depicting the relatedness of the background
MLST genotypes. The P1 progeny (including P1 variants) are
all in the cluster with ST695 as the founder genotype. ST695
is a single-locus variant of ST899, differing only at xpt (allele
113) as a result of a 39-codon deletion in the middle of the xpt
gene. This truncated xpt allele was ﬁrst identiﬁed in 1999
among US strains [31] and was present in ST2363
19A and
ST2284
4. ST2363 and ST2284 differ from ST695 at spi and
recP, respectively. The truncated xpt allele is identical to xpt
allele 10 apart from the large deletion, thus allele 113
probably derived from the full-length allele 10 (Table 1; http://
www.mlst.net/).
The P2 progeny (including the P2variant) appeared to evolve
from the founder ST247
4 clonal complex. The oldest known
strains of ST247
4 were identiﬁed in The Netherlands in 1978,
and ST247
4 and the related single-locus variants in the
ST247
4 cluster have been detected in other European and
South American countries through at least 2005 (Figure 3;
http://www.mlst.net/). The P2 progeny were ﬁrst identiﬁed in
2005 in the US. ST247
4 strains have not yet been charac-
terised, thus recombinational crossover points in P2 progeny
have not yet been identiﬁed. The third serotype 19A capsular
change was the P3 progeny (ST899
19A); Figure 3 depicts the
relatedness of this ST to other STs in the clonal complex.
Sequence Diversity among PBPs
Alterations in PBP genes pbp2x, pbp1a, and pbp2b confer
penicillin resistance [24–26]. Allele assignments were given to
each unique pbp2x and pbp1a sequence among this collection
of strains; the pbp2x and pbp1a sequences from TIGR4, a
serotype 4 penicillin-susceptible strain, were used for
comparison and designated allele 1 (Table 1; Figure 4). All
R1,R 2, and P3 strains possessed pbp2x and pbp1a alleles similar
to those in TIGR4, which correspond to the basal penicillin
minimum inhibitory concentration (MIC) of 0.03 lg/ml that is
typical of all ST695
4 isolates. Among D3,D 4, and P2 strains,
pbp2x was altered while pbp1a was largely conserved; both
Figure 2. Sequencing Results among Progeny, Donor, and Recipient Pneumococci, including Differences in pbp2x and pbp1a Genes
P1 and P1variants, and the P2 and P2variant, are each represented by one P1 and P2 schematic, respectively, for simplicity. Unique regions of sequence are
indicated by variations of shading and patterns, e.g. D1,P 1,D 4,P 2 all have the same pbp2x sequence (black), whereas R1 has a different pbp2x sequence
(speckled).
(A) Schematic of the recombinational crossover points revealed in the major group of progeny strains, ST695
19A. Three SNPs marked and confirmed the
upstream crossover region and two SNPs marked and confirmed the downstream crossover region in the progeny strains, as shown with black arrows.
The length of the recombinational fragment was 38.6 kb (10.3 kb upstream þ 18.6 kb capsular locus þ 9.7 kb downstream).
(B) Illustration of the second recombinational event. ST2365
19A is identical to ST645
19A in the entire sequenced region; no obvious crossover points have
yet been revealed and the recipient is unknown.
doi:10.1371/journal.ppat.0030168.g002
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strains. Phenotypically, strains with altered pbp2x and pbp1a
genes resulted in a MIC to penicillin of 0.06–0.12 lg/ml (Table
1). The breakpoints for penicillin resistance are  0.06 lg/ml
(susceptible), 0.12–1.0 lg/ml (intermediate resistance), and  2
lg/ml (high-level resistance), but the variation in suscepti-
bility testing is 61 doubling dilution [34]. All donor strains
and all progeny strains apart from the P3 strain had MIC
values at the penicillin-susceptible breakpoint; however,
based on the pbp2x and pbp1a sequences, D1,D 2,P 1, and
P1variants had divergent PBPs typical of penicillin-nonsuscep-
tible strains ([24–26]; Figure 4). All pbp sequences in this study
were unique to the National Center for Biotechnology
Information database.
Resistance to Other Antimicrobials
Among all strains, four donor and ﬁve vaccine escape
strains were erythromycin resistant, possessing the mef(A)
efﬂux phenotype [29,35]; all ﬁve vaccine escape strains and
two donors (cdc8 and cdc9) were conﬁrmed to be mef(A)-
positive by PCR ([36,37]; Lesley McGee, Emory University,
personal communication). The other donor strains were not
tested by PCR. One erythromycin-resistant donor strain (D4)
was also clindamycin resistant (Table 1). D1 and D2 donor
strains were co-trimoxazole resistant, and one vaccine escape
strain (cdc13) was resistant to tetracycline. One P1var2 strain
(cdc44) was resistant to chloramphenicol; R2 was resistant to
chloramphenicol and levoﬂoxacin.
Discussion
To our knowledge, this is the ﬁrst report of vaccine escape
events in the US subsequent to national pneumococcal
vaccination. The main event resulted in nonvaccine serotype,
penicillin-nonsusceptible ST695
19A pneumococci as a result
of recombination between the recipient ST695
4 and donor
ST199
19A (D1). A second event resulted in the emergence of
ST2365
19A from the well-established serotype 4 clonal
complex of ST247, and these strains had a different serotype
19A donor, ST645
19A. No recipient has yet been identiﬁed,
but recipient strains of ST247 will be characterised to
elucidate the recombinational crossover points in these
progeny. Finally, a third event resulted in the emergence of
ST899
19A, but the serotype 19A donor is not yet known.
The most plausible explanation for the emergence of these
strains is that one main recombinational event, ST695
19A,
occurred around 2003, and the fact that it was a nonvaccine
serotype variant provided the selective advantage by which
these strains could evade the immune pressures invoked by
the vaccine. Furthermore, with the additional selective
advantage of penicillin nonsusceptibility, this progeny strain
increased in frequency over the next 2 y, disseminating
through the northeastern US to become the fourth most
common serotype 19A genetic complex in the US (ABC
surveillance program, unpublished data). The recombina-
tional event did not appear to result in a decrease in ﬁtness
among these strains, as strains increased over time within the
population. More worryingly, all of these strains were
recovered from patients with bacteremia and meningitis.
We cannot be absolutely certain that ST695
19A strains never
existed pre-vaccination, but extensive surveillance pre- and
post-vaccination in the US failed to reveal any such strains
[14,31], and no such strains have been reported to the MLST
database from other parts of the world. Hence, even if these
strains did exist pre-vaccination they were likely to be very
rare, and it could still be maintained that the immune
Figure 3. eBURST Analysis of Closely Related STs Found in This Study and in the MLST Database (http://www.mlst.net/) as of March 2007
STs described in the current study are indicated with arrows and boxes. The size of each circle is proportional to the number of isolates of that ST, the
blue circle indicates the founder, ST247, of the entire clonal complex, and the yellow circles indicate subgroup founders (STs that have at least two
single-locus variants). Strains from the ST247 founder complex have been recovered throughout Europe, South America, and the US (ST2365 recovered
only in the US), from 1978 to 2005. The allelic profile of ST247 is aroE 16, gdh 13, gki 4, recP 5, spi 6, xpt 10, and ddl 14. Strains from the ST246 subgroup
have been detected in Spain, Australia, and the United Kingdom from 1997 to 2005; strains from the ST899 subgroup have been recovered in the US
and the Czech Republic from 1999 to 2002; and strains of the ST695 subgroup have been detected in the US and South Africa from 1999 to 2005.
Pneumococcal strains of all STs in this diagram are serotype 4 except where indicated; however, the serotype 19A strains have only been reported in the
US to date, and only since 2003. P1,P 1var6,P 2, and P3 refer to the type of progeny strains (see Table 1).
doi:10.1371/journal.ppat.0030168.g003
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e168 1633
Pneumococcal Vaccine Escapepressure resulting from PCV7 use selected for the emergence
of such strains.
The two additional progeny strain types, ST2365
19A and
ST899
19A, were identiﬁed in 2005, and this may be the very
early detection of these new recombinants. Whether or not
these strains will increase in prevalence remains to be seen.
Since serotype 19A was the major replacement disease
serotype to emerge post-vaccination [15,17], our efforts to
understand the genetics of this event have been focused on
serotype 19A strains. This will be expanded to include other
putative capsular switching events to better understand the
phenomenon of capsular switching. Although it has been
known for many years that capsular switching can and does
occur, it is not at all clear how often it occurs within the
pneumococcal population.
An exciting component of the current study is that
recombination in the pneumococcus has been revealed
almost as it occurred. This presents a unique opportunity
to measure recombination in nature as a result of vaccine-
induced changes, and may shed light on how much
recombination occurs in general within the pneumococcal
genome. Studies to explore these strains in detail are
ongoing.
What are the implications for vaccine escape? Clearly,
vaccine escape by recombination at the capsular locus has the
very real potential to reduce PCV7 effectiveness in the longer
term. This will almost certainly be true for any serotype-
speciﬁc pneumococcal vaccine, given the diversity and
complexity of serotypes possessed by the pneumococcus.
These US data reinforce two key points: i) the importance of
surveillance pre- and post-vaccination in countries preparing
to implement PCV7, to detect changes as and when they
occur; and ii) the importance of understanding the genetic
events that result in vaccine escape. Discerning the genetic
event is crucial to understanding vaccine escape and
pneumococcal recombination in general. Such knowledge
will provide guidance about the design and use of future
pneumococcal vaccines.
Materials and Methods
Invasive pneumococcal strains were collected as part of the ABC
surveillanceprogramattheCDC.Microbiologicaltestingandmolecular
characterisation by MLST was performed as previously described
[14,31]. Strains for this study were selected from pre- and post-vaccine
implementation ABC collections and sent to the University of Oxford.
Sequence alignments of the TIGR4 [38], R6 [39], and Spain
23F-1 (http://
www.sanger.ac.uk/Projects/S_pneumoniae/) pneumococcal genomes
were used to design 51 sets of PCR primers (available upon request)
in regions upstream and downstream of the capsular locus (Figure 1).
DNA was extracted from pneumococcal strains using the DNeasy
Tissue Kit (Qiagen UK). PCR assays were identical for all combina-
tions of PCR primers: 2.5 ll of PCR buffer (Qiagen), 0.5 ll of dNTPs
(200 lM stock), 0.5 ll of forward primer (100 lM stock), 0.5 llo f
reverse primer (100 lM stock), 0.3 ll of Taq polymerase (Qiagen UK),
19.7 ll of nuclease-free water (Invitrogen UK), and 1 ll( ;1 lg) of
extracted DNA. Thirty-ﬁve cycles of PCR ampliﬁcation were
performed: denaturation at 94 8C for 30 s, annealing at 55 8C for
30 s, and elongation at 72 8C for 60 s. Ten-microliter sequencing
reactions were prepared with 4 ll primer (1 lM stock of PCR
primers), 1.75 ll sequencing buffer (Applied Biosystems), 0.5 ll Big
Dye (Applied Biosystems), 1.75 ll nuclease-free water, and 2 ll
cleaned PCR amplicons; followed by 25 sequencing cycles of 96 8C for
10 s, 50 8C for 5 s, and 60 8C for 2 min. PCR amplicons and sequencing
products were cleaned as described previously [15].
Sequences were assembled and edited using Pregap4 and Gap4
(Staden Package, http://staden.sourceforge.net/). Consensus sequences
were aligned using Multalin [40] and trimmed to the longest possible
consensus sequence shared by all strains. Trimmed sequences were
uploaded into MEGA version 3.1 [41], and compared in an iterative
process to ascertain which strains were donors of the 19A capsule and
reveal recombinational crossover points in progeny strains. The
eBURST algorithm was used to compare all progeny strains to all
pneumococcal strains represented in the MLST database [42].
Supporting Information
Figure S1. Sequence Alignments of Major Donor, Recipient, and
Progeny Strains in This Study, Aligned with the Corresponding
Region of the TIGR4 Sequence
Polymorphic sites are shown across the entire sequenced region
upstream and downstream of the capsular locus. Black arrows
highlight the SNPs in the upstream and downstream crossover
regions; the locations of pbp2x, pbp1a, and the (missing) capsular locus
are also shown. Strains are labeled A and B to correspond to the
strains involved in the two main recombinational events shown in
Figure 2.
Found at doi:10.1371/journal.ppat.0030168.sg001 (95 KB PPT).
Figure 4. Sequence Alignments of pbp2x and pbp1a (2,253 and 2,160 Base Pairs, Respectively, in Total Length), Showing the Polymorphic Sites
(Numbered Vertically) in Each of the PBP Alleles Present in This Dataset
Note that pbp1a is reverse complemented. Allele 1 for each gene corresponds to the penicillin-susceptible TIGR4 pneumococcal strain [38]. Pbp1a_allele
5 and pbp1a_allele 5rec are identical apart from base pairs 1784 and 2009, which mark the downstream recombinational crossover point in progeny
strains ST695
19A.
doi:10.1371/journal.ppat.0030168.g004
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